Cullinan Therapeutics (CGEM) had its "buy" rating reaffirmed by BTIG Research. They now have a $38.00 price target on the stock.
Cullinan Therapeutics (CGEM) had its price target raised by HC Wainwright from $27.00 to $30.00. They now have a "buy" rating on the stock.
U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Cullinan Therapeutics (CGEM) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
Cullinan Therapeutics (CGEM) had its price target raised by Wedbush from $34.00 to $36.00. They now have an "outperform" rating on the stock.